Skip to content Skip to footer

Rising Costs of Cancer Treatments

The industry that makes cancer drugs, including well known companies such as Novartis and Pfizer, typically sell the public on the idea that the costs and risks of researching, developing, and bringing a new cancer drug to market justify the accompanying (and sometimes prohibitive) price tag.  Dr. Peter Bach, the Director for the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, posits that the validity of this argument has lost credibility and has more to do with what the market will bear than what the industry actually spends on development.

Dr. Bach uses the example of two cancer drugs, Xalkori and Zykadia, which target the same type of lung cancer.  Xalkori is produced by Pfizer and was introduced in 2011, while Zykadia, produced by Novartis, came to market in 2014.  Despite the fact that Pfizer had much more risk in bringing Xalkori to market than Pfizer did with Zykadia, by virtue of being the first drug of its type to come available, Zykadia costs $1700 more per month than the older, more established drug it imitates.  Dr. Bach believes that discrepancy correlates with the cancer drug market in 2014 tolerating higher prices than it did in 2011.  Further, today’s prices are more than double what the market would bear a decade ago.  The pricing for cancer drugs, as well as the drugs for many other diseases, no longer reflects reality, logic, or how a true market should perform.

Read the full article on Forbes, “Cancer: Unpronounceable Drugs, Incomprehensible Prices

How Fifth Season Helps Cancer Patients With Costs of Cancer Treatments

Fifth Season Financial provides people with advanced stage cancer an option to relieve financial stress through its Funds for Living Program. The program allows eligible individuals to obtain immediate cash by taking a loan against a qualifying life insurance policy.  A loan from Fifth Season is paid by the policy’s death benefit, thus relieving the patient of any obligation to repay it during his or her lifetime, and no burden is transferred to the estate. This money can be used at your own discretion, whether you want use it to pay for cancer treatments or whatever else you’d like to do with the money. Regaining financial control allows patients to focus on treatment, health, and family, which is Fifth Season’s ultimate goal.

See if you qualify

Office
201 Broad Street
Suite 500
Stamford, CT 06901

BBB Accredited Business since 09/05/2006

Legal Notices:
Fifth Season Financial, L.P. (“Fifth Season”) is a licensed consumer lender in certain states. Loans being made or arranged by Fifth Season to California residents are made or arranged pursuant to a California Financing Law license, California lender license #603 E043. Loans being made or arranged by Fifth Season to Texas residents are made or arranged pursuant to a Texas Regulated Lender License, Texas lender license #14000508545-151373. This site is directed at, and made available to, persons in the continental U.S., Alaska and Hawaii only. The Funds for Living Program is not available to residents of all states. Fifth Season’s principal place of business is 201 Broad Street, Suite 500, Stamford, CT 06901, Phone 855.45.FUNDS.

Confidentiality & Privacy Policy | Legal Notices & Terms of Use

Fifth Season Financial, L.P. | 2022. All Rights Reserved.

This website and its content shall not constitute a solicitation or advertisement in any state where Fifth Season Financial LP is not permitted to make a loan to residents of that State